Brought to you by 
Cirius Therapeutics gets $30mm in first closing of Series A round
18 Apr 2017
Executive Summary
Cirius Therapeutics Inc. (formerly Octeta Therapeutics; developing a treatment for nonalcoholic steatohepatitis) raised $30mm through the first closing of what the company hopes will turn out to be a $40mm Series A round. Frazier Healthcare Partners and Novo AS led, and were joined by Adams Street Partners, Renaissance Venture Capital Fund, and Hopen Life Science Ventures. Fraizer and Novo get seats on the company’s board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cirius Therapeutics gets $30mm in first closing of Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice